{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Bone&page=23", "query": { "condition": "Cancer Bone", "page": 23 }, "page_size": 10 }, "pagination": { "page": 23, "page_size": 10, "total_count": 3411, "total_pages": 342, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Bone&page=24&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Bone&page=22&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T19:33:50.221Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00952289", "title": "COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "MPN (Myeloproliferative Neoplasms)" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 309, "start_date": "2009-08", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2018-03-12", "last_synced_at": "2026-11-15T19:33:50.221Z", "location_count": 88, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Baldwin Park, California + 85 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Baldwin Park", "state": "California" }, { "city": "Bellflower", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00952289" }, { "nct_id": "NCT02702960", "title": "Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fibrolamellar Hepatocellular Carcinoma", "Hepatocellular Carcinoma (Fibrolamellar Variant)", "Hepatocellular Carcinoma" ], "interventions": [ { "name": "living related donor partial liver transplantation", "type": "PROCEDURE" }, { "name": "Total body irradiation", "type": "RADIATION" }, { "name": "Bone marrow transplant from same donor", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Antithymocyte globulin", "type": "DRUG" }, { "name": "fludarabine", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "RADIATION", "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "16 Years to 65 Years" }, "enrollment_count": 0, "start_date": "2016-03", "completion_date": "2018-01-03", "has_results": false, "last_update_posted_date": "2018-06-15", "last_synced_at": "2026-11-15T19:33:50.221Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02702960" }, { "nct_id": "NCT00933985", "title": "Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Leukemias of Ambiguous Lineage", "Acute Undifferentiated Leukemia", "Angioimmunoblastic T-cell Lymphoma", "Blastic Phase Chronic Myelogenous Leukemia", "Childhood Burkitt Lymphoma", "Childhood Chronic Myelogenous Leukemia", "Childhood Diffuse Large Cell Lymphoma", "Childhood Immunoblastic Large Cell Lymphoma", "Childhood Nasal Type Extranodal NK/T-cell Lymphoma", "Cutaneous B-cell Non-Hodgkin Lymphoma", "Hepatosplenic T-cell Lymphoma", "Intraocular Lymphoma", "Noncutaneous Extranodal Lymphoma", "Peripheral T-cell Lymphoma", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Anaplastic Large Cell Lymphoma", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Relapsing Chronic Myelogenous Leukemia", "Small Intestine Lymphoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "dexrazoxane hydrochloride", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "obatoclax mesylate", "type": "DRUG" }, { "name": "liposomal vincristine sulfate", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 22, "start_date": "2009-06", "completion_date": "2013-04", "has_results": false, "last_update_posted_date": "2014-05-01", "last_synced_at": "2026-11-15T19:33:50.221Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Orange, California • Washington D.C., District of Columbia + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00933985" }, { "nct_id": "NCT06641089", "title": "Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthritis, Psoriatic" ], "interventions": [ { "name": "Sonelokimab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Risankizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MoonLake Immunotherapeutics AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 600, "start_date": "2024-10-15", "completion_date": "2027-09-13", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-11-15T19:33:50.221Z", "location_count": 44, "location_summary": "Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 41 more", "locations": [ { "city": "Avondale", "state": "Arizona" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Flagstaff", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06641089" }, { "nct_id": "NCT00096213", "title": "S0344 Intralesional Resection in Treating Patients With Chondrosarcoma of the Bone", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcoma" ], "interventions": [ { "name": "conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2004-12", "completion_date": "2009-08", "has_results": false, "last_update_posted_date": "2012-01-18", "last_synced_at": "2026-11-15T19:33:50.221Z", "location_count": 23, "location_summary": "Little Rock, Arkansas • Aurora, Colorado • Gainesville, Florida + 14 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Royal Oak", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00096213" }, { "nct_id": "NCT02749708", "title": "Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia (AML)", "Myelodysplastic Syndrome (MDS)", "Chronic Myelomonocytic Leukemia (CMML)" ], "interventions": [ { "name": "IRX5183", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 13, "start_date": "2017-01-30", "completion_date": "2018-08-14", "has_results": false, "last_update_posted_date": "2019-04-22", "last_synced_at": "2026-11-15T19:33:50.221Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02749708" }, { "nct_id": "NCT00887068", "title": "Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Leukemia", "AML", "MDS" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 187, "start_date": "2009-04-21", "completion_date": "2018-08-20", "has_results": true, "last_update_posted_date": "2020-01-14", "last_synced_at": "2026-11-15T19:33:50.221Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00887068" }, { "nct_id": "NCT03609840", "title": "Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hematologic Malignancies", "Nonmalignant Diseases", "Immune Deficiency", "Hemoglobinopathies", "Genetic Inborn Errors of Metabolism", "Fanconi Anemia", "Thalassemia", "Sickle Cell Disease" ], "interventions": [ { "name": "Thiotepa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "17 Years", "sex": "ALL", "summary": "Up to 17 Years" }, "enrollment_count": 25, "start_date": "2017-05-24", "completion_date": "2023-07-31", "has_results": false, "last_update_posted_date": "2023-09-21", "last_synced_at": "2026-11-15T19:33:50.221Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03609840" }, { "nct_id": "NCT04256317", "title": "A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Myelodysplastic Syndromes", "Acute Myeloid Leukemia", "Myelodysplastic Syndrome/Neoplasm", "Chronic Myelomonocytic Leukemia" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "ASTX030 (cedazuridine + azacitidine)", "type": "DRUG" }, { "name": "Cedazuridine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 316, "start_date": "2020-05-21", "completion_date": "2028-11-01", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-11-15T19:33:50.221Z", "location_count": 24, "location_summary": "Los Angeles, California • Orange, California • New Haven, Connecticut + 18 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04256317" }, { "nct_id": "NCT05558696", "title": "A Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Polycythemia Vera (IMG-7289-CTP-203/MK-3543-004)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Polycythemia Vera" ], "interventions": [ { "name": "Bomedemstat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2023-09-07", "completion_date": "2025-07-10", "has_results": true, "last_update_posted_date": "2026-05-07", "last_synced_at": "2026-11-15T19:33:50.221Z", "location_count": 8, "location_summary": "Plantation, Florida • Skokie, Illinois • Ann Arbor, Michigan + 5 more", "locations": [ { "city": "Plantation", "state": "Florida" }, { "city": "Skokie", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05558696" } ] }